Cite
HARVARD Citation
Lebwohl, M. et al. (2021). Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study. Journal of the European Academy of Dermatology and Venereology. pp. 1152-1160. [Online].